PWT143 (ME-401) is primarily investigated for its potential in cancer treatment, particularly in targeting specific pathways involved in tumor growth. It functions as a selective inhibitor of PI3K delta, a protein kinase that plays a critical role in cell proliferation and survival. By inhibiting this pathway, it may help in slowing down or stopping the progression of certain cancers, especially hematologic malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Research is ongoing to explore its efficacy and safety in clinical trials, with a focus on optimizing dosing and minimizing side effects. Its targeted approach offers promise for developing more precise and effective therapies for patients with these conditions.